Multiple Myeloma Coverage from Every Angle
Editors:
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Advertisement
Advertisement

Recent News

FDA Grants Fast Track Designation for CLR 131 in Multiple Myeloma
ASCO 2019: Lenalidomide vs. Observation in Smoldering Multiple Myeloma
Immunoglobulin Lambda Translocation and Treatment Resistance in Multiple Myeloma
Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies
Novel Selective HDAC6 Inhibitor Under Study in Multiple Myeloma
Severe Obesity and Outcomes After Transplant for Myeloma
Allogeneic CAR T-Cell Therapy to Enter Phase I Trial in Multiple Myeloma
Role of Mesenchymal Stem Cells in Progression of Multiple Myeloma
FDA Warns of Risks Associated With Investigational Use of Venetoclax in Multiple Myeloma
Real-World Findings With Ixazomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
Modeling Renal Injury in Multiple Myeloma
Challenges in Precision Medicine Strategies in Multiple Myeloma
Perlmutter Cancer Center Receives Anonymous Gift of $75 Million for New Blood Cancer Center
Does Intensive Therapy Improve Survival in Patients With Multiple Myeloma?
Daratumumab Split-Dosing Regimen for Multiple Myeloma Approved by the FDA
Researchers Launch Study of Precursor Conditions of Multiple Myeloma
African Ancestry and Genetic Alterations Leading to Multiple Myeloma
European Commission Approves Split-Dose of Daratumumab in Multiple Myeloma
Quadruplet Versus Triplet Therapy for Multiple Myeloma
Studying Heterogeneity in Myeloma via Single-Cell RNA Sequencing
Early Results of Phase I Study of CAR T-Cell Therapy in Multiple Myeloma
Novel Four-Drug Combination Therapy for Newly Diagnosed Multiple Myeloma
First-in-Class Agent Targets NF-kB Signaling in Multiple Myeloma
Venetoclax Combination Therapy for Resistant Multiple Myeloma
ASH 2018: First-Line Combination Regimens in Transplant-Ineligible Patients With Myeloma
ASH 2018: Novel Agent for Resistant Multiple Myeloma Under Study
ASH 2018: Is Urine Immunofixation Necessary to Define Complete Remission in Myeloma
ASH 2018: Frailty-Adjusted Treatment Approach for Elderly Patients With Myeloma
ASH 2018: Ixazomib Maintenance After Transplantation in Newly Diagnosed Multiple Myeloma
ASH 2018: Double vs. Single Autologous Transplantation in Newly Diagnosed Myeloma
ASH 2018: Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
ASH 2018: Transplant Versus Continuous Lenalidomide-Based Therapy for Relapsed Multiple Myeloma
Myeloma Crowd Launches Free Online Resource for Patients With Multiple Myeloma
FDA Grants Regenerative Medicine Advanced Therapy Designation to CAR T-Cell Therapy
Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.